following an abbreviated submission:
medroxyprogesterone acetate injection (Sayana® Press) is accepted for use within NHS Scotland.
Indication under review: for long-term female contraception. Each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). However, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year.
In adolescents (12-18years), use of medroxyprogesterone acetate injection is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with medroxyprogesterone acetate injection during the critical period of bone accretion.
Sayana® Press contains medroxyprogesterone acetate for subcutaneous injection at a similar cost to the existing deep intramuscular injection.
Download detailed advice80KB (PDF)
Medicine details
- Medicine name:
- medroxyprogesterone acetate (Sayana Press)
- SMC ID:
- 896/13
- Indication:
- For long-term female contraception. Each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). However, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 September 2013